Form D · Pharmaceuticals
Anacor Pharmaceuticals, Inc.
Palo Alto, CA · CIK 0001411158
Offering snapshot reported Jun 17, 2013 · SEC filing
- Reported sold
- $0 Offering amount: $2.7M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 7, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2013 | Initial | $0 | No comparison | 2 | SEC filing |
| Apr 9, 2013 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Mar 31, 2011 | Initial | $0 | No comparison | 2 | SEC filing |
| Dec 3, 2010 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Jan 8, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $450K (estimated)
- Form D file number
- 021-198076
Total offering amount above represents maximum aggregate exercise price of Warrants issued on June 7, 2013
Warrants exercisable for Common Stock and Common Stock issuable upon exercise of such Warrants
Finder's fee of up to $450,000 payable for the loan transaction entered into in connection with this offering.
Source: Form D, filed Jun 17, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Berns | Director |
| Sanjay Chanda | Executive |
| Irwin Heyman | Executive |
| Zhi Hong | Director |
| Anders Hove | Director |
| Paul Klingenstein | Director |
| Mark Leschly | Director |
| Kirk Maples | Executive |
| Richard Markham | Director |
| Geoffrey Parker | Executive |
| David Perry | Director, Executive |
| Jacob Plattner | Executive |
| William Rieflin | Director |
| Lucy Shapiro | Director |
| Lee Zane | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1020 E. Meadow Circle
Palo Alto, CA, 94303
Palo Alto, CA, 94303